The flavoprotein FOXRED2 reductively activates nitro-chloromethylbenzindolines and other hypoxia-targeting prodrugs
- PMID: 24632291
- DOI: 10.1016/j.bcp.2014.03.001
The flavoprotein FOXRED2 reductively activates nitro-chloromethylbenzindolines and other hypoxia-targeting prodrugs
Abstract
The nitro-chloromethylbenzindoline prodrug SN29428 has been rationally designed to target tumour hypoxia. SN29428 is metabolised to a DNA minor groove alkylator via oxygen-sensitive reductive activation initiated by unknown one-electron reductases. The present study sought to identify reductases capable of activating SN29428 in tumours. Expression of candidate reductases in cell lines was modulated using forced expression and, for P450 (cytochrome) oxidoreductase (POR), by zinc finger nuclease-mediated gene knockout. Affymetrix microarray mRNA expression of flavoreductases was correlated with SN29428 activation in a panel of 23 cancer cell lines. Reductive activation and cytotoxicity of prodrugs were measured using mass spectrometry and antiproliferative assays, respectively. SN29428 activation under hypoxia was strongly attenuated by the pan-flavoprotein inhibitor diphenyliodonium, but less so by knockout of POR suggesting other flavoreductases contribute. Forced expression of 5-methyltetrahydrofolate-homocysteine methyltransferase reductase (MTRR), as well as POR, increased activation of SN29428 in hypoxic HCT 116 cells. SN29428 activation strongly correlated with expression of POR and also FAD-dependent oxidoreductase domain containing 2 (FOXRED2), in cancer cell lines. This association persisted after removing the effect of POR enzyme activity using first-order partial correlation. Forced expression of FOXRED2 increased SN29428 activation and cytotoxicity in hypoxic HEK293 cells and also increased activation of hypoxia-targeted prodrugs PR-104A, tirapazamine and SN30000, and increased cytotoxicity of the clinical-stage prodrug TH-302. Thus this study has identified three flavoreductases capable of enzymatically activating SN29428, one of which (FOXRED2) has not previously been implicated in xenobiotic metabolism. These results will inform future development of biomarkers predictive of SN29428 sensitivity.
Keywords: FOXRED2; Hypoxia-targeting prodrug; NitroCBI; PR-104; TH-302; Tirapazamine.
Copyright © 2014 Elsevier Inc. All rights reserved.
Similar articles
-
Diflavin oxidoreductases activate the bioreductive prodrug PR-104A under hypoxia.Mol Pharmacol. 2012 Jan;81(1):31-40. doi: 10.1124/mol.111.073759. Epub 2011 Oct 7. Mol Pharmacol. 2012. PMID: 21984255
-
Identification of one-electron reductases that activate both the hypoxia prodrug SN30000 and diagnostic probe EF5.Biochem Pharmacol. 2014 Oct 15;91(4):436-46. doi: 10.1016/j.bcp.2014.08.003. Epub 2014 Aug 15. Biochem Pharmacol. 2014. PMID: 25130546
-
Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: comparison with other hypoxia-activated prodrugs.Biochem Pharmacol. 2012 Mar 1;83(5):574-85. doi: 10.1016/j.bcp.2011.12.005. Epub 2011 Dec 13. Biochem Pharmacol. 2012. PMID: 22182429
-
Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.Anticancer Drug Des. 1999 Dec;14(6):473-86. Anticancer Drug Des. 1999. PMID: 10834269 Review.
-
Design of anticancer prodrugs for reductive activation.Med Res Rev. 2009 Jan;29(1):29-64. doi: 10.1002/med.20137. Med Res Rev. 2009. PMID: 18688784 Review.
Cited by
-
Knockdown of FOXRED2 restrains proliferation, invasion and migration of human melanoma cells.Heliyon. 2023 Nov 30;9(12):e22588. doi: 10.1016/j.heliyon.2023.e22588. eCollection 2023 Dec. Heliyon. 2023. PMID: 38076169 Free PMC article.
-
Hypoxia-targeted drug delivery.Chem Soc Rev. 2019 Feb 4;48(3):771-813. doi: 10.1039/c8cs00304a. Chem Soc Rev. 2019. PMID: 30575832 Free PMC article. Review.
-
Quinoxaline 1,4-di-N-Oxides: Biological Activities and Mechanisms of Actions.Front Pharmacol. 2016 Mar 21;7:64. doi: 10.3389/fphar.2016.00064. eCollection 2016. Front Pharmacol. 2016. PMID: 27047380 Free PMC article. Review.
-
Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials.Clin Transl Radiat Oncol. 2019 Jan 18;15:62-69. doi: 10.1016/j.ctro.2019.01.005. eCollection 2019 Feb. Clin Transl Radiat Oncol. 2019. PMID: 30734002 Free PMC article.
-
How Are Proteins Reduced in the Endoplasmic Reticulum?Trends Biochem Sci. 2018 Jan;43(1):32-43. doi: 10.1016/j.tibs.2017.10.006. Epub 2017 Nov 15. Trends Biochem Sci. 2018. PMID: 29153511 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials